| NCT06072781 | III | Recurrent low grade serous ovarian cancer | A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) | AZ, AR, CA, CT, FL, GA, IL, LA, MD, MI, MN, MO, NY, NC, OH, OK, OR, PA, TX, UT, VA | View Drugs | View Results |
Avutometinib | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 | RAF and MEK inhibitor | Clinical Trials | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials |
|
|
| NCT03682289 | II | Advanced solid tumors with ARID1A or ATM alterations | Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies | CA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03734692 | II | Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rintatolimod | Atvogen | TLR3 agonist and immune cell stimulator | Approved in Other Indications |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | CAPE, Xeloda | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02710253 | II | Advanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy) | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | TX | View Drugs | View Results |
Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03994796 | II | Advanced solid tumors with brain metastases and NTRK, ROS1, KRAS G12C, CDK pathway or PI3K pathway alterations | Genomically-Guided Treatment Trial in Brain Metastases | AK, AZ, AR, CA, CO, FL, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Adagrasib | MRTX849, KRAS G12C inhibitor MRTX849 | KRAS G12C inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Paxalisib | GDC-0084, PI3K inhibitor GDC-0084, RG7666 | PI3K/mTOR inhibitor | Clinical Trials |
|
|
| NCT04387227 | II | Recurrent ovarian cancer (only detectable by rising CA125) | A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Carboplatin to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer | WA | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04449549 | II | Recurrent granulosa cell ovarian cancer or clear cell ovarian cancer | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04469764 | II | Recurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterations | An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer | CA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Anastrozole | Arimidex | Aromatase inhibitor | | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04482309 | II | Advanced HER2+ (IHC1+, IHC2+ or IHC3+) solid tumors | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) | CA, IL, IN, MA, NJ, NY, TX, WA | View Drugs | View Results |
Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Ovarian Cancer |
|
|
| NCT04550494 | II | Advanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; germ-line BRCA MUT patients must have progressed on prior PARP inhibitor) | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | FL, MD, OK | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04589845 | II | Advanced solid tumors with alterations in ALK, ATM, KRAS G12C, NTRK1/2/3, ROS1 or SETD2 | Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial | CA, CO, ID, MD, MI, MN, MT, NE, NJ, NY, OH, PA, TN, TX, VA, WA, WI | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Camonsertib | RP-3500 | ATR kinase inhibitor | Clinical Trials | Divarasib | GDC-6036 | KRAS G12C inhibitor | Clinical Trials | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04771520 | II | Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I) | Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors | TX | View Drugs | |
Avapritinib | | PDGFRa and c-Kit inhibitor | Approved in Other Cancers |
|
|
| NCT02896335 | II | Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A | A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway | MA | View Drugs | View Results |
Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04919629 | II | Recurrent ovarian cancer with symptomatic ascites or pleural effusion | Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion | NY | View Drugs | |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Pegcetacoplan | C3-targeted complement inhibitor APL-2, APL-2 | Blocks the cleavage of C3 | Approved in Other Indications | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04957615 | II | Advanced solid tumors with ARID1A mutations | A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors | TX | View Drugs | |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05064280 | II | Advanced solid tumors with brain metastases | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | TX | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05071937 | II | Recurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens) | Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05113368 | II | Recurrent low grade serous ovarian cancer | Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial | OH | View Drugs | |
Fulvestrant | ZD9238, ICI 182,780, Faslodex | ER antagonist (SERD) | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers |
|
|
| NCT05185947 | II | Recurrent or persistent ovarian cancer with peritoneal disease (IP/IV) | Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04992013 | II | Ovarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS) | Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS | MA | View Drugs | View Results |
|
|
| NCT05231122 | II | Recurrent serous, endometrioid or clear cell ovarian cancer | Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer | NY, TX | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | CDX-1140 | | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05286801 | II | Advanced solid tumors with loss of SMARCB1 or SMARCA1 | A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | AL, CA, CO, DC, GA, IL, IN, MD, MA, MI, MN, MO, NY, NC, OH, OR, PA, TN, TX, UT, WA, WI | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tiragolumab | MTIG7192A, RO7092284 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells | Clinical Trials |
|
|
| NCT05296512 | II | Recurrent or persistent clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell component | A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary | IL, MA, MN | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05327010 | II | Advanced solid tumors with alterations in BARD1, BRCA 1/2, BRIP1, FANCA, PALB2; RAD51 or RAD51C/D with prior PARP inhibitor therapy or advanced solid tumors with a KRAS MUT or platinum sensitive ovarian cancer without BRCA1/2 mutations with CR/PR on prior PARP inhibitor | Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET) | CA, CO, CT, FL, GA, IL, KS, KY, LA, MD, MO, NC, PA, TX, UT, VA | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05489211 | II | Advanced solid tumors | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours | CA, IN, MA, MI, NJ, NM, NY, OH, TN, TX, WI | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Datopotamab deruxtecan | Dato-DXd, Anti-TROP2/DXd antibody-drug conjugate DS-1062a | ADC: anti-TROP2 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT05512208 | II | Recurrent high grade serous, endometrioid or mucinous ovarian cancer with alterations in RAS, BRAF or NF1 | A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK) | NM, OK | View Drugs | View Results |
Avutometinib | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 | RAF and MEK inhibitor | Clinical Trials | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials |
|
|
| NCT05523440 | II | Recurrent ovarian cancer with ARID1A mutations | Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A) | OK | View Drugs | |
|
|
| NCT05554367 | II | Advanced solid tumors with alterations in BRAF, HRAS, KRAS, NRAS or RAF, or low grade serous ovarian cancer with progression on prior MEK inhibitor | Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial | AL, CO, FL, ID, IL, IA, KY, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TX, VA, WA, WV, WI | View Drugs | View Results |
Binimetinib | MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi | MEK inhibitor | Approved in Other Cancers | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT05503797 | II | Advanced solid cancers with a BRAF fusion | A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations | CA, FL, MD, MA, MN, MO, NE, NJ, NY, OH, RI, TX, WA, WV | View Drugs | |
Cobicistat | GS 9350 | CYP3A inhibitor | Approved in Other Indications | Plixorafenib | 8394, BRAF inhibitor PLX8394, FORE8394 | BRAF kinase inhibitor | Clinical Trials |
|
|
| NCT05147558 | II | Recurrent carcinosarcoma | A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas | NJ, NY | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05634785 | II | Advanced CD30+ nonseminomatous germ cell tumors | Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT) | NC | View Drugs | |
ATLCAR.CD30 | autologous CD30CAR-CD28-CD3zeta-expressing T lymphocytes | Immune response against cancer expressing CD30 | Clinical Trials |
|
|
| NCT05638295 | II | Advanced solid tumors with a KRAS G12C mutation | A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial | AL, FL, ID, IL, IA, KY, ME, MD, MI, MN, MO, MT, NV, NJ, NM, NY, OH, OK, OR, PA, VA, WA, WI | View Drugs | |
Panitumumab | Vectibix, ABX-EGF, Clone E7.6.3, ABX-EGF Monoclonal Antibody | EGFR antagonist | | Sotorasib | AMG 510, KRAS mutant-targeting AMG 510, Sotorasib | KRAS G12C inhibitor | Approved in Other Cancers |
|
|
| NCT05642780 | II | Recurrent ovarian cancer | A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | IN, MN, NY, TX, VA | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Sacituzumab tirumotecan | sac-TMT, MK-2870, SKB264 | ADC: anti-TROP2 + topoisomerase I inhibitor (KL610023) | Clinical Trials |
|
|
| NCT05673928 | II | Advanced HER2+ solid tumors with brain metastases | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | TX | View Drugs | |
Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT05700721 | II | Advanced solid tumors with active brain metastases and with alterations in ATM, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, RAD51, RAD51B/C/D, RAD52, or RAD54L | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | TX | View Drugs | |
Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05798611 | II | Advanced solid tumors with dMMR or high MSI | A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST) | CA, IL, MA, NY, OK, PA, RI | View Drugs | |
ART0380 | | ATR kinase inhibitor | Clinical Trials |
|
|
| NCT05983276 | II | Recurrent ovarian cancer | Combination of the Hypomethylating Agent Decitabine and the Nuclear Export Receptor XPO-1 Inhibitor Selinexor to Reverse Platinum Resistance in Relapsed/Refractory Epithelial Ovarian Cancer | IL | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Decitabine | dezocitidine, deoxyazacytidine, 5-aza-dCyd, Dacogen | DNA methylation inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Selinexor | selective inhibitor of nuclear export KPT-330, CRM1 nuclear export inhibitor KPT-330, KPT-330, Xpovio | Selective inhibition of nuclear export (SINE) | Approved in Other Cancers |
|
|
| NCT06126276 | II | Advanced solid tumors with ERBB2 AMP | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial | AL, ID, IL, IA, ME, MD, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, TX, VA, WI | View Drugs | |
Neratinib | HKI-272, PD272 | EGFR, HER2, HER4 kinase inhibitor | Approved in Other Cancers | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT05787561 | II | Recurrent or persistent mesonephric or mesonephric-like gynecologic cancer; no prior FAK, RAF or MEK inhibitor | Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer | NJ, NY | View Drugs | View Results |
Avutometinib | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 | RAF and MEK inhibitor | Clinical Trials | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials |
|
|
| NCT06281678 | II | Advanced solid tumors | A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies | TX | View Drugs | View Results |
IBI363 | anti-PD-1/IL-2 bispecific antibody fusion protein IBI363 | Stimulates IL-2R to increase T and NK cell activation and immune response and blocks PD-L1/2 inhibition of T cells | Clinical Trials |
|
|
| NCT06433219 | II | Platinum sensitive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations or HRD+ with progression on prior PARP inhibitor maintenance therapy | An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deļ¬ciency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302) | VA | View Drugs | View Results |
Lartesertib | ataxia telangiectasia mutated kinase inhibitor M4076, M4076 | ATM kinase inhibitor | Clinical Trials | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer | Tuvusertib | ATR kinase inhibitor M1774, M1774 | ATR kinase inhibitor | Clinical Trials |
|
|
| NCT05032040 | II | Platinum resistant high grade serous or recurrent clear cell ovarian cancer (at most 2 prior chemotherapy regimens) | A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer | AZ, CA, CO, DE, GA, NY, PA, TX, VA | View Drugs | View Results |
Vudalimab | XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717 | Blocks PD-1 and CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT05405595 | Ib/II | Advanced solid tumors (Phase II) | A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors | AZ, CA, FL | View Drugs | View Results |
Muzastotug | anti-CTLA-4 monoclonal antibody ADG126, anti-CTLA-4 SAFEbody ADG126, ADG126 | Blocks CTLA-4 inhibition of T cells | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03872947 | Ib | Recurrent ovarian cancer | A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors | AZ, CA, NJ, NY, OR, TX | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism | Clinical Trials |
|
|
| NCT04130516 | I/IIa | Advanced solid tumors with prior PD-1/PD-L1 inhibitor therapy (Phase II) | A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab | CA, CT, MA, NM, NY, PA, TX | View Drugs | View Results |
LNS8801 | G protein-coupled estrogen receptor agonist LNS8801 | GPER agonist | Clinical Trials |
|
|
| NCT05123482 | I/IIa | Recurrent B7H4+ ovarian cancer | A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) | CA, LA, MD, MA, MO, NM, NY, NC, PA, TX | View Drugs | View Results |
Puxitatug samrotecan | AZD8205 | ADC: anti-B7H4 + topoisomerase I inhibitor (AZ14170132) | Clinical Trials | Rilvegostomig | AZD2936, anti-PD-1/anti-TIGIT bispecific antibody AZD2936 | Block TIGIT signaling and PD-1 interaction with PD-L1 and PD-L2 to increase NK and T cell activation and immune response | Clinical Trials |
|
|
| NCT02484404 | I/II | Recurrent ovarian cancer (Phase II) | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | MD | View Drugs | View Results |
Cediranib | Recentin, Cediranib maleate, AZD2171 | VEGFR1-3 kinase inhibitor | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03157128 | I/II | Advanced solid tumors with RET alterations (Phase II) | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | AZ, CA, CO, CT, DC, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI | View Drugs | View Results |
Selpercatinib | LOXO-292, RET kinase inhibitor LOXO-292, Retevmo | RET-kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03767348 | I/II | Advanced solid tumor with high MSI or dMMR who have progressed on prior PD-1/PD-L1 inhibitor therapy - intratumoral injection (Phase II) | An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors | AZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, SC, TN, TX, UT, WA | View Drugs | View Results |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | RP1 | oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT04262466 | I/II | Advanced PRAME+ solid tumors - optional subcutaneous injection (Phase II) | Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers | CA, CO, DC, FL, IL, IA, MA, NJ, NY, OK, PA, SC, TN, TX, UT, WA, WI | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Brenetafusp | IMC-F106C, a T cell redirecting bi-specific biologic, IMC-F106C | Re-directs T cells to attack PRAME+ tumor cells | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03093116 | I/II | Advanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II) | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, NC, OH, PA, TN, TX, VA, WA, WI | View Drugs | View Results |
Repotrectinib | TPX-0005, ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005 | ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03175224 | I/II | Advanced solid tumors with MET amplifications or MET gene fusions (Phase II) | Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | CA, DE, FL, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, WV, WI | View Drugs | View Results |
Vebreltinib | CBT-101, APL-101, Bozitinib | c-Met kinase inhibitor | Clinical Trials |
|
|
| NCT04561362 | I/II | Advanced solid tumors (Phase II) | Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies | CO, FL, NY, OH, PA, TN, TX | View Drugs | View Results |
BT8009 | BT8009 - a Nectin-4-targeting Bicycle Toxin Conjugate, BT8009-100 | ADC: anti-Nectin-4 + microtubule destabilizer (MMAE) | Clinical Trials |
|
|
| NCT04590326 | I/II | Recurrent ovarian cancer | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3) | CA, FL, IL, MA, MI, NY, OH, PA, WA | View Drugs | View Results |
Cemiplimab | anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | REGN5668 | | Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cells | Clinical Trials | Ubamatamab | REGN4018, anti-MUC16/CD3 bispecific antibody REGN4018 | Re-directs T cells to attack MUC16 (CA125)+ tumor cells | Clinical Trials |
|
|
| NCT04243499 | I/II | Recurrent ovarian cancer with high levels of Ī³9Ī“2 T cells | A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer | CT, TX, WA | View Drugs | View Results |
ICT01 | | Activates gamma/delta T cells to stimulate immune response | Clinical Trials |
|
|
| NCT04826341 | I/II | Advanced solid tumors with alterations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D, or RAD54L or HRD+ or high LOH with progression on or within 6 months after prior PARP inhibitor treatment (Phase II) | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | MD | View Drugs | View Results |
Berzosertib | ATR kinase inhibitor VX-970, VE-822, M6620, VX-970 | ATR kinase inhibitor | Clinical Trials | Sacituzumab govitecan | Trodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132 | ADC: anti-TROP2 + topoisomerase I inhibitor (SN38) | Approved in Other Cancers |
|
|
| NCT04665206 | I/II | Advanced solid tumors with inactivating NF2 mutations/alterations or YAP/TAZ gene rearrangements (Phase II) | Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (Mutant NF2 or mNF2) | IL, MA, NY, TX | View Drugs | View Results |
VT3989 | | TEAD inhibitor | Clinical Trials |
|
|
| NCT04956640 | I/II | Advanced solid tumors with a KRAS G12C mutation (Phase II) | A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors | AL, CA, CT, FL, IN, LA, MA, NH, NY, NC, PA, TN, TX, UT, VA, WI | View Drugs | View Results |
Olomorasib | LY3537982 | KRAS G12C inhibitor | Clinical Trials |
|
|
| NCT05118789 | I/II | Advanced solid tumors with ROS1 rearrangement (Phase II) | A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1) | CA, CO, DC, FL, MA, MI, MO, NY, NC, OH, PA, TN, VA, WA | View Drugs | View Results |
NVL-520 | | ROS1 kinase inhibitor | Clinical Trials |
|
|
| NCT05262530 | I/II | Recurrent CLDN6+ ovarian cancer | First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors | IN, MD, NY, NC, PA, TX, VA | View Drugs | |
BNT142 | BNT142 RiboMab (mRNA-encoded antibody) | Re-directs T cells to attack CLDN6+ tumor cells | Clinical Trials |
|
|
| NCT03190941 | I/II | Advanced solid tumors with a RAS G12V mutation | A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | MD | View Drugs | |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Anti-KRAS G12V mTCR PBL | | Immune response against cancer expressing RAS G12V | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT06040970 | I/II | Platinum sensitive ovarian cancer | A Single-Center, Open-Label, Single-Arm, Phase I Study With Dose Expansion Cohort of Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer | NY | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Sacituzumab govitecan | Trodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132 | ADC: anti-TROP2 + topoisomerase I inhibitor (SN38) | Approved in Other Cancers |
|
|
| NCT06065462 | I/II | Recurrent clear cell ovarian cancer without a PPP2R1A mutation | Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | TX | View Drugs | View Results |
Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | LB-100 | protein phosphatase 2A inhibitor LB-100 | PP2A inhibitor | Clinical Trials |
|
|
| NCT05579366 | I/II | Recurrent ovarian cancer (Phase II) | Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors | AZ, CA, FL, KS, MD, MA, MI, MN, OK, RI, TN, TX, UT, VA | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Rinatabart sesutecan | PRO1184 | ADC: anti-FRalpha + topoisomerase I inhibitor (exatecan) | Clinical Trials |
|
|
| NCT05592626 | I/II | Advanced solid tumors (Phase II) | A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001) | FL, MD, MA, NY, OH | View Drugs | |
STAR0602 | anti-TCR Vb6/Vb10/IL-2 antibody fusion protein STAR0602 | Activates alpha/beta T cells to stimulate immune response | Clinical Trials |
|
|
| NCT05920798 | I/II | Recurrent ovarian cancer; all lesions must be less than 5 cm | FRĪ±DCs Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer | MN | View Drugs | View Results |
FRalpha DC vaccine | Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, FRalphaDCs | Immune response against cancer expressing folate receptor | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02264678 | I | Platinum sensitive ovarian cancer with BRCA1/2, PALB2 or RAD51C/D mutations, or HRD+ that must have progressed on PARP inhibitor, no prior ATR inhibitor | A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies. | CA, PA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | AZD2281, Lynparza | PARP inhibitor | Approved in Ovarian Cancer | Saruparib | AZD5305 | PARP1 inhibitor | Clinical Trials |
|
|
| NCT03821935 | I | Recurrent Granulosa Cell Tumors (no prior PD-1 inhibitor therapy) | A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors | AR, CT, FL, IN, MO, MT, NY, OH, TN, TX | View Drugs | View Results |
Budigalimab | ABBV-181, anti-PD1 monoclonal antibody ABBV-181 | Blocks PD-L1/2 inhibition of T cells | Clinical Trials | Livmoniplimab | anti-GARP monoclonal antibody ABBV-151, ARGX-115, ABBV-151 | Binds GARP in complex with inactive TGF-beta preventing release of active TGF-beta | Clinical Trials |
|
|
| NCT03905148 | I | Advanced solid tumors with NRAS alterations (in expansion) | A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors | CA, TX | View Drugs | View Results |
Lifirafenib | BRAF/EGFR inhibitor BGB-283, BGB-283, Lifirfenib | BRAF and EGFR inhibitor | Clinical Trials | Mirdametinib | MEK inhibitor PD0325901, PD-0325901 | MEK inhibitor | Clinical Trials |
|
|
| NCT03968406 | I | Recurrent ovarian cancer (amenable to radiation therapy) - without ascites | Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers | MD, TX | View Drugs | View Results |
Radiation Therapy | Irradiation, Radiotherapy | | | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04249843 | I | Advanced solid tumors with BRAF mutations Class II: K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, G469S or BRAF fusion or BRAF V600 tumors with progression after prior BRAF inhibitor or MEK inhibitor (in expansion) | A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors | CA, LA, MA, NY, TX, VA | View Drugs | View Results |
Brimarafenib | BGB-3245 | BRAF kinase inhibitor | Clinical Trials |
|
|
| NCT04315233 | I | Recurrent serous ovarian cancer | A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE) | UT, VA | View Drugs | View Results |
Belinostat | PXD101 | HDAC inhibitor | Approved in Other Cancers | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04329494 | I | Recurrent ovarian cancer with peritoneal disease | Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) | CA, FL, NY | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers | PIPAC | pressurized intraperitoneal aerosol chemotherapy | | Clinical Trials |
|
|
| NCT04516447 | I | Recurrent ovarian cancer (in expansion) | A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer | CO, MA, MO, NY, NC, RI, TX | View Drugs | View Results |
Azenosertib | ZN-c3 | WEE1 inhibitor | Clinical Trials | Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04673448 | I | Recurrent ovarian cancer with BRCA1/2 mutations | Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer | WA | View Drugs | View Results |
Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | MK4827, Zejula | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04703920 | I | Recurrent high grade serous ovarian cancer | A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | MI | View Drugs | View Results |
Belinostat | PXD101 | HDAC inhibitor | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04707248 | I | Recurrent ovarian cancer (in expansion) | Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | AZ, CO, FL, OK, TN | View Drugs | View Results |
Raludotatug deruxtecan | DS-6000a | ADC: anti-CDH6 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT04855656 | I | Advanced solid tumors with CCNE1 amplification or alterations in FBXW7 or PPP2R1A (in expansion) | Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors | CT, MA, MO, NY, RI, TX, UT, VA | View Drugs | View Results |
Camonsertib | RP-3500 | ATR kinase inhibitor | Clinical Trials | Debio 0123 | | WEE1 inhibitor | Clinical Trials | Lunresertib | RP-6306 | PKMYT1 inhibitor | Clinical Trials |
|
|
| NCT04890613 | I | Ovarian cancer with germline BRCA2 or germline PALB2 alterations, or high grade serous or endometrioid ovarian cancer with BRCA1 alterations or other HRD-associated mutations | Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation | CA, FL, MA, OH, PA | View Drugs | View Results |
Pidnarulex | Pol I inhibitor CX5461, RNA Pol I inhibitor CX5461, CX-5461 | Pol I inhibitor | Clinical Trials |
|
|
| NCT05057715 | I | Persistent or recurrent serous ovarian cancer | Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer | PA | View Drugs | View Results |
huCART-meso cells | | Immune response against cancer expressing mesothelin | Clinical Trials | VCN-01 | PH20 hyaluronidase-expressing adenovirus VCN-01 | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT05103683 | I | Advanced solid tumors (in ovarian expansion) | A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer | CA, MN, OH | View Drugs | View Results |
TORL-1-23 | | ADC: anti-CLDN6 + microtubule destabilizer (MMAE) | Clinical Trials |
|
|
| NCT05109975 | I | Recurrent high grade ovarian cancer with CCNE1 AMP | A Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-tumor Activity | MI, NY, TX, WI | View Drugs | View Results |
Debio 0123 | | WEE1 inhibitor | Clinical Trials |
|
|
| NCT05216432 | I | Advanced solid tumors with a PIK3CA mutation (in ovarian expansion) | A First-in-Human Study of Mutant-selective PI3KĪ± Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | AZ, CA, CO, FL, IL, IN, MA, MI, MO, NJ, NY, TN, TX, VA, WI | View Drugs | View Results |
RLY-2608 | | PI3K alpha inhibitor | Clinical Trials |
|
|
| NCT05238922 | I | Advanced solid tumors (in ovarian expansion) | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | CA, CO, GA, NY, PA, TX | View Drugs | View Results |
INCB123667 | | CDK2 inhibitor | Clinical Trials |
|
|
| NCT05271318 | I | Recurrent ovarian cancer | A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer. | MN, NY | View Drugs | View Results |
Igrelimogene litadenorepvec | TNFalpha/IL-2-encoding oncolytic adenovirus TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2, TILT-123 | Induces immune response and tumor cell lysis | Clinical Trials | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05346484 | I | Advanced solid tumors - optional intratumoral injection (in expansion) | A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST). | AZ, AR, CA, FL, MI, OH, UT, VA | View Drugs | View Results |
CF33-hNIS | CF33-hNIS (hNIS - human sodium iodide symporter), VAXINIA, HOV2 | Induces immune response and tumor cell lysis | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05394675 | I | Advanced solid tumors (inc ovarian expansion) | A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6) | CO, FL, MI, TN, TX | View Drugs | View Results |
DS-9606a | | ADC: anti-CLDN6 + DNA damaging agent (PBD dimers) | Clinical Trials |
|
|
| NCT05417594 | I | Recurrent ovarian cancer with a BRCA1/2, PALB2 or RAD51C/D alteration (monotherapy, at most 1 prior PARP inhibitor therapy) or advanced HER2+ solid tumors (combo w/ trastuzumab deruxtecan) or advanced solid tumors (combo w/ datopotamab deruxtecan) | A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1) | CA, IL, MA, NY, TX | View Drugs | View Results |
AZD9574 | | PARP1 inhibitor | Clinical Trials | Datopotamab deruxtecan | Dato-DXd, Anti-TROP2/DXd antibody-drug conjugate DS-1062a | ADC: anti-TROP2 + topoisomerase I inhibitor (Dxd) | Clinical Trials | Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Ovarian Cancer |
|
|
| NCT05527184 | I | Recurrent high grade serous ovarian cancer (inc expansion) | A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRĪ± Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | CA, CO, FL, MI, NY, OK, TN, TX | View Drugs | |
IMGN151 | | ADC: anti-FRalpha + microtubule destabilizer (DM21) | Clinical Trials |
|
|
| NCT03401385 | I | Advanced solid tumors (in expansion) | Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01) | CA, DC, GA, MD, MA, NY, TN, TX, VA | View Drugs | View Results |
Datopotamab deruxtecan | Dato-DXd, Anti-TROP2/DXd antibody-drug conjugate DS-1062a | ADC: anti-TROP2 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT03745326 | I | Advanced solid tumors with a RAS G12D mutation | A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | MD | View Drugs | |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Anti-KRAS G12D mTCR PBL | | Immune response against cancer expressing RAS G12D | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT05787587 | I | Recurrent HRD+ ovarian cancer and advanced solid tumors with alterations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCA/L, NBN, PALB2, PPP2R2A, RAD51B/C/D, RAD54L or high LOH or HRD+ (in ovarian expansion) | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | CA, CO, CT, GA, MA, MI, NV, NY, OK, PA, TN, TX, UT, VA, WA, WI | View Drugs | |
Darovasertib | IDE161 | PARG inhibitor | Clinical Trials |
|
|
| NCT05942300 | I | Platinum sensitive ovarian cancer | Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Tulmimetostat | CPI-0209, EZH2 inhibitor CPI-0209 | EZH2 histone methyltransferase inhibitor | Clinical Trials |
|
|
| NCT05950464 | I | Recurrent clear cell or endometrioid ovarian cancer or platinum resistant high grade serous ovarian cancer (inc ovarian expansion) | A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer | GA, IL, IA, MI, OH, OK, PA, RI, WI | View Drugs | View Results |
Tuvusertib | ATR kinase inhibitor M1774, M1774 | ATR kinase inhibitor | Clinical Trials | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05989724 | I | Advanced solid tumors (inc ovarian expansion) | A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors | AZ, MI, NC, OK, TX | View Drugs | |
SON-DP | transcription factor protein SON-DP | Induces pluripotent reprogramming in cancer cells and generates transient induced pluripotent stem cells (tiPSCs) | Clinical Trials |
|
|
| NCT06342986 | I | Recurrent ovarian cancer with prior bevacizumab - intraperitoneal infusion | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | MN | View Drugs | |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | FT536 | | Immune response against cancer expressing MICA/B | Clinical Trials |
|
|
| NCT06469281 | I | Recurrent ovarian cancer with CA125 levels at least 2 x ULN (inc expansion) | A Phase 1a/1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NJ | View Drugs | |
27T51 | | Immune response against cancer expressing MUC16 (CA125) | Clinical Trials | Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Cemiplimab | anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04847063 | I | Newly diagnosed or recurrent ovarian cancer with peritoneal disease | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | MD | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers | HIPEC | Hyperthermic Intraperitoneal Chemotherapy | | NCCN Guidelines for Ovarian Cancer | Oxaliplatin | OHP, Eloxatine, Dacplat, Dacotin, Eloxatin | DNA damaging agent | | Surgery | | | Clinical Trials |
|
|
| NCT05039801 | I | Advanced solid tumors with AKT, KEAP1, NF1, NFE2L2, PIK3CA, PTEN or STK11 (LKB1) alterations, or platinum resistant or refractory high grade serous ovarian cancer with low expression of ASNS, or recurrent clear cell ovarian cancer with an ARID1A mutation or platinum resistant high grade ovarian cancer (combo w/ paclitaxel and bevacizumab) (inc expansion) | A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors | TX | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Capivasertib | AZD5363, Akt inhibitor AZD5363 | pan-AKT inhibitor | Approved in Other Cancers | IACS-6274 | glutaminase inhibitor IPN60090, IPN60090 | Glutaminase inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04457089 | early_phase1 | Platinum sensitive ovarian cancer | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | CA | View Drugs | |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Simvastatin | MK 733, synvinolin | HMG-CoA reductase inhibitor | |
|
|